Crossmark

A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes

Crossref DOI link: https://doi.org/10.1007/s00213-022-06178-6

Published Online: 2022-06-23

Published Print: 2022-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chapman, Fiona https://orcid.org/0000-0002-4429-1060
McDermott, Simon

Rudd, Kathryn

Taverner, Victoria

Stevenson, Matthew

Chaudhary, Nveed

Reichmann, Kerstin

Thompson, Joseph

Nahde, Thomas

O’Connell, Grant
Funding

Funding for this research was provided by:

Imperial Brands plc
License Information

Text and Data Mining valid from 2022-06-23

Version of Record valid from 2022-06-23
More Information

Article History

Received: 23 December 2021

Accepted: 14 June 2022

First Online: 23 June 2022

Declarations

:

: All the authors were employed by Imperial Brands PLC either during part or all of the study. Skruf Snus A.B., Sweden, is a wholly owned subsidiary of Imperial Brands PLC and is the manufacturer of the two nicotine pouch products investigated in this study.

Document is current

Any future updates will be listed below